Amalia Schiel
Overview
Explore the profile of Amalia Schiel including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
61
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Chapela S, Muscogiuri G, Barrea L, Frias-Toral E, Burgos H, Ricart M, et al.
Anaesthesiol Intensive Ther
. 2023 Feb;
54(5):357-364.
PMID: 36734445
Introduction: Sepsis is a syndrome of physiological, pathological, and biochemical disorders with several processes co-occurring; reactive oxygen species (ROS) production and apoptosis are 2 of them. Succinate is a Krebs...
2.
Chapela S, Burgos I, Schiel A, Alonso M, Alberto Stella C
Anaesthesiol Intensive Ther
. 2021 Mar;
53(2):126-133.
PMID: 33788508
Introduction: Oxidative stress is one of the pathophysiological processes that occur during sepsis. Reactive oxygen species (ROS) production causes lipid peroxidation and protein and DNA damage. ROS and DNA damage...
3.
Trimarchi H, Canzonieri R, Costales-Collaguazo C, Politei J, Stern A, Paulero M, et al.
Clin Kidney J
. 2019 Feb;
12(1):53-60.
PMID: 30747154
Background: In Fabry nephropathy, podocyturia is an early event that may lead to glomerulosclerosis and chronic kidney disease. The glycocalyx is a potential podocyte damaged compartment in glomerulopathies. We investigated...
4.
Trimarchi H, Canzonieri R, Schiel A, Costales-Collaguazo C, Stern A, Paulero M, et al.
Nephron Extra
. 2017 Jun;
7(2):52-61.
PMID: 28626472
Background: Podocyturia may determine the evolution to podocytopenia, glomerulosclerosis, and renal failure. According to the Oxford classification of IgA nephropathy (IgAN), the S1 lesion describes glomerulosclerosis. Urokinase-type plasminogen activator receptor...
5.
Trimarchi H, Canzonieri R, Schiel A, Politei J, Costales-Collaguazo C, Stern A, et al.
Int J Nephrol
. 2017 May;
2017:1287289.
PMID: 28523190
. Despite enzyme replacement therapy, Fabry nephropathy still progresses. Podocyturia is an irreversible event that antedates proteinuria and leads to chronic renal failure. We evaluated a potential mechanism of podocyte...
6.
Trimarchi H, Canzonieri R, Schiel A, Politei J, Stern A, Andrews J, et al.
J Nephrol
. 2016 Mar;
29(3):459-460.
PMID: 27015899
No abstract available.
7.
Trimarchi H, Canzonieri R, Schiel A, Politei J, Stern A, Andrews J, et al.
J Nephrol
. 2016 Feb;
29(6):791-797.
PMID: 26842625
Background: Proteinuria suggests kidney involvement in Fabry disease. We assessed podocyturia, an early biomarker, in controls and patients with and without enzyme therapy, correlating podocyturia with proteinuria and renal function....
8.
Zazzetti F, Rivero M, Duartes Noe D, Gallacher A, Schiel A, Khoury M, et al.
Reumatol Clin
. 2011 Jul;
6(6):299-302.
PMID: 21794737
Unlabelled: Twenty to 71% of patients with Sjögren's syndrome (SS) will develop systemic manifestations. Objective: To characterize the clinical-serological presentation and the frequency of systemic manifestations in patients with primary...
9.
Trimarchi H, Genoud V, Schiel A, Castanon M, Freixas E, Diaz M, et al.
Medicina (B Aires)
. 2002 Jun;
62(2):149-53.
PMID: 12038037
Homocysteine is a risk factor for cardiovascular disease. Mutations in a key enzyme in homocysteine metabolism, methylenetetrahydrofolate reductase, may contribute to hyperhomocysteinemia and alter folate and cobalamin levels. After starting...
10.
Trimarchi H, Schiel A, Freixas E, Diaz M
Nephron
. 2002 May;
91(1):58-63.
PMID: 12021520
Background: There are no data available on the effects of intravenous (i.v.) methylcobalamin (Me-Cbl), the coenzymatically active form of vitamin B12 that acts as a cofactor for methionine synthase in...